A Phase 1/2 interventional study of Placebo gel and GLYC-101 gel (1.0 %) in Wounds, sponsored by TR Therapeutics. Completed at 1 site in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-28.
Sponsored by TR Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.
The proposed pilot-study will document feasibility, safety and efficacy of topically applied Glucoprime gel (GLYC-101 gel 1.0 %) in promoting wound healing in healthy volunteer subjects undergoing retro-auricular Carbon Dioxide Laser Skin Resurfacing (CO2 LSR). The study will observe the effects of the topical agent over the course of 1 month following the treatment. as a preparation for study GLYC-101-1b (Double-blind, randomized, placebo-controlled Phase 2 Pilot Study to investigate the safety and efficacy of 1.0 % topically applied GLYC 101 compared to placebo, in patients undergoing Carbon Dioxide Laser Skin Resurfacing).
2,218 studies on the registry are indexed under Wounds and Injuries; 441 are open to participants now.
This study's enrollment of 12 is below the median of 70 across 1,424 interventional studies indexed under Wounds and Injuries.
Browse Wounds and Injuries studies →TR Therapeutics is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects meeting all of the following criteria will be considered for admission to the study:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GLYC-101 Active Retro-auricular Site (1 per participant)
Drug: GLYC-101 gel (1.0 %)
Placebo Retro-auricular Site (1 per participant) This arm undergoes laser ablation with subsequent Placebo gel administration
Drug: Placebo gel
Administration of Placebo gel on Day 1, 3 and 5 post ablation.
Administration on Day 1, 3 and 5 post laser ablation.
Time to Complete Wound Closure (Epithelialization)
Subjects were evaluated every 2 days from the time of the laser procedures for the first 10 days and then seen every 2 weeks for 4 weeks. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.
Time frame: Over the course of 1 month following the initial treatment.
Percentage of Wound Epithelialized
The percentage of wound epithelialized was assessed at Day 15 post laser ablation.
Time frame: Day 15 post laser ablation.
Recruitment occurred in March 2008 at a single site, Clinical Testing Center of Beverly Hills, Beverly Hills, California, United States, 90210.
| Milestone | GLYC-101 and Placebo |
|---|---|
| Started | 12 |
| Completed | 11 |
| Not completed | 1 |
| Withdrew: Other reason | 1 |
Subjects were evaluated every 2 days from the time of the laser procedures for the first 10 days and then seen every 2 weeks for 4 weeks. Efficacy was assessed based on the time to complete epithelialization in terms of the number of days from Day 1 (day of laser ablation) to the day on which complete epithelialization was observed.
| days | GLYC-101 Active Retro-auricular Site (1 Per Participant) | Placebo Retro-auricular Site (1 Per Participant) |
|---|---|---|
| Time to Complete Wound Closure (Epithelialization) | 15 (15 to 15) | 15 (15 to 15) |
The percentage of wound epithelialized was assessed at Day 15 post laser ablation.
| percent | GLYC-101 Active Retro-auricular Site (1 Per Participant) | Placebo Retro-auricular Site (1 Per Participant) |
|---|---|---|
| Percentage of Wound Epithelialized | 100 | 100 |
Collected over Adverse Events (AEs) were collected over the course of 1 month.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GLYC-101 and Placebo | — | 0/12 (0%) | 12/12 (100%) |
| Event | GLYC-101 and Placebo |
|---|---|
| ErythemaSkin and subcutaneous tissue disorders | 12/12 |
| HeadacheNervous system disorders | 11/12 |
| Ear PruritusEar and labyrinth disorders | 3/12 |
| GranulomaGeneral disorders | 1/12 |
| Age, Categorical(Participants) | GLYC-101 and Placebo |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 12 |
| >=65 years | 0 |
| Age, Continuous(years) | GLYC-101 and Placebo |
|---|---|
| Mean | 50.3 ± 8.93 |
| Sex: Female, Male(Participants) | GLYC-101 and Placebo |
|---|---|
| Female | 12 |
| Male | 0 |
| Region of Enrollment(participants) | GLYC-101 and Placebo |
|---|---|
| United States | 12 |
The record gives a start of Mar 2008, a primary completion of Apr 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Yeast .beta.-d-glucan